Clinical trials are growing more complex, and nowhere is that more evident than in oncology and obesity research. As sponsors push for reliable, real-time patient data, the role of electronic clinical outcome assessments (eCOAs) has never been more critical. These tools determine not only how patients report on their quality of life but also how sponsors capture the endpoints that drive regulatory approval. In this episode of the AI in Business podcast, Emerj Editorial Director Matthew DeMello speaks with Anthony Mikulaschek, Vice President of Commercial Strategy at IQVIA Technologies. Anthony unpacks the evolution of eCOAs, from their early days on Palm Pilots to today's AI-enabled platforms. He explains how thoughtful design reduces patient and clinician burden, why cultural and linguistic nuance matters for global trials, and what digital libraries and compliance automation mean for faster, more resilient studies. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related